Information Provided By: 
Fly News Breaks for December 15, 2016
GRFS, HOLX
Dec 15, 2016 | 07:51 EDT
Canaccord analyst Mark Massaro said he was surprised Grifols (GRFS) agreed to pay "lofty 7.9x multiple" of $1.85B in cash to acquire Hologic's (HOLX) share of their joint blood screening business. Massaro believes the deal makes long-term strategic sense for Hologic and should drive long-term shareholder value. He keeps a Buy rating and $48 price target on Hologic shares.
News For HOLX;GRFS From the Last 2 Days
There are no results for your query HOLX;GRFS
